BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 17763325)

  • 1. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
    He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
    Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
    Jones-Trower A; Garcia A; Meseda CA; He Y; Weiss C; Kumar A; Weir JP; Merchlinsky M
    Virology; 2005 Dec; 343(1):128-40. PubMed ID: 16165184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.
    Kaever T; Matho MH; Meng X; Crickard L; Schlossman A; Xiang Y; Crotty S; Peters B; Zajonc DM
    J Virol; 2016 May; 90(9):4334-4345. PubMed ID: 26889021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
    Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
    Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of human immunological responses to vaccinia virus.
    Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
    Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
    Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
    Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
    Shinoda K; Wyatt LS; Irvine KR; Moss B
    Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.
    Midgley CM; Putz MM; Weber JN; Smith GL
    J Gen Virol; 2008 Dec; 89(Pt 12):2992-2997. PubMed ID: 19008384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.
    Frey SE; Newman FK; Kennedy JS; Ennis F; Abate G; Hoft DF; Monath TP
    Vaccine; 2009 Mar; 27(10):1637-44. PubMed ID: 19071184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.